Table 3.
Clinicopathological manifestations of the IgAN patients at baseline, grouped by the platelet to albumin ratio.
| Variables | Unmatched Cohort | Matched Cohort | ||||
|---|---|---|---|---|---|---|
| Low PAR group | High PAR group | P | Low PAR group | High PAR group | P | |
| Numbers (%) | 723 (74.8) | 243 (25.2) | 115 (66.9) | 57 (33.1) | ||
| Age at diagnosis (years) | 33 (26-42) | 33 (24-43) | 0.808 | 35.2 ± 11.5 | 33.2 ± 12.1 | 0.292 |
| Male (%) | 343 (47.4) | 100 (41.2) | 0.102 | 53 (46.1) | 22 (38.6) | 0.415 |
| Smoking (%) | 126 (17.4) | 46 (18.9) | 0.628 | 18 (15.7) | 8 (14.0) | 0.826 |
| Drinking (%) | 156 (21.6) | 54 (22.2) | 0.857 | 19 (16.5) | 10 (17.5) | 1.000 |
| SBP (mmHg) | 125 (115-137) | 124 (114-140) | 0.779 | 127.9 ± 18.3 | 127.8 ± 18.2 | 0.957 |
| DBP (mmHg) | 83.1 ± 13.2 | 83.4 ± 14.3 | 0.731 | 82.8 ± 14.0 | 83.1 ± 16.6 | 0.891 |
| Hypertension (%) | 186 (25.7) | 71 (29.2) | 0.314 | 31 (27.0) | 11 (19.3) | 0.346 |
| Proteinuria (g/24 h) | 1.10 (0.66-2.11) | 2.53 (1.29-5.8) | <0.001 | 2.00 (1.00-3.00) | 2.00 (1.00-3.00) | 0.337 |
| U-RBC (/HP) | 18 (6-63) | 22 (7-80) | 0.197 | 23 (6-80) | 24 (7-71) | 0.090 |
| PLT (×109/L) | 172 (137-201) | 265 (232-301) | <0.001 | 170.5 ± 45.7 | 277.8 ± 59.5 | <0.001 |
| ALB (g/L) | 41.4 (38.4-44.2) | 35.4 (28.3-39.5) | <0.001 | 40.1 (37.1-43.3) | 36.4 (31.6-40.8) | <0.001 |
| e-GFR (ml/min/1.73m2) | 93.03 (67.50-116.56) | 94.00 (60.13-134.26) | 0.593 | 83.82 ± 32.09 | 93.06 ± 37.86 | 0.096 |
| sCr (umol/L) | 83.0 (66.0-108.4) | 81.9 (62.0-112.0) | 0.227 | 103.1 ± 48.5 | 95.8 ± 56.6 | 0.375 |
| Hb (g/L) | 133 (120-148) | 132 (117-145) | 0.217 | 131.4 ± 21.5 | 127.2 ± 20.7 | 0.222 |
| Anemia (%) | 216 (29.9) | 75 (30.9) | 0.809 | 39 (33.9) | 21 (36.8) | 0.376 |
| M0/M1 (%) | 183/540 (25.3/74.7) | 52/191 (21.4/78.6) | 0.228 | 34/81 (29.6/70.4) | 10/47 (17.5/82.5) | 0.098 |
| E0/E1 (%) | 703/20 (97.2/2.8) | 222/21 (91.4/8.6) | <0.001 | 115/0 (100/0) | 56/1 (99.4/1.8) | 0.331 |
| S0/S1 (%) | 279/444 (38.6/61.4) | 93/150 (38.3/61.7) | 0.939 | 35/80 (30.4/69.6) | 22/35 (38.6/61.4) | 0.350 |
| T0/T1-2 (%) | 586/137 (81.1/18.9) | 185/58 (76.1/23.9) | 0.116 | 86/29 (74.8/25.2) | 42/15 (73.7/26.3) | 1.000 |
| C0/C1-2 (%) | 564/159 (78.0/22.0) | 173/70 (71.2/28.8) | 0.036 | 81/34 (70.4/29.6) | 37/20 64.9/35.1) | 0.488 |
| Immunosuppressive therapy | 387 (53.5) | 182 (74.9) | <0.001 | 75 (65.2) | 39 (68.3) | 0.734 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; U-RBC, the count of uric red blood cell; ALB, albumin; sCr, serum creatinine; e-GFR, estimated glomerular filtration rate; Hb, hemoglobin; PLT, platelet; M, mesangial proliferation; E, endocapillary proliferation; S, segmental glomerulosclerosis; C, crescents; T, tubular atrophy/interstitial fibrosis.
Bold values was that the differences were significant.